Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 203

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

Cudkowicz, M.E., Shefner, J.M., Schoenfeld, D.A., Brown Jr., R.H., Johnson, H., Qureshi, M., Jacobs, M., Rothstein, J.D., Appel, S.H., Pascuzzi, R.M., Heiman-Patterson, T.D., Donofrio, P.D., David, W.S., Russell, J.A., Tandan, R., Pioro, E.P., Felice, K.J., Rosenfeld, J., Mandler, R.N., Sachs, G.M., Bradley, W.G., Raynor, E.M., Baquis, G.D., Belsh, J.M., Novella, S., Goldstein, J., Hulihan, J. · 2003 · Neurology

Abstract

OBJECTIVE: To determine if long-term topiramate therapy is safe and slows disease progression in patients with ALS. METHODS: A double-blind, placebo-controlled, multicenter randomized clinical trial was conducted. Participants with ALS (n = 296) were randomized (2:1) to receive topiramate (maximum tolerated dose up to 800 mg/day) or placebo for 12 months. The primary outcome measure was the rate of change in upper extremity motor function as measured by the maximum voluntary isometric contraction (MVIC) strength of eight arm muscle groups. Secondary endpoints included safety and the rate of decline of forced vital capacity (FVC), grip strength, ALS functional rating scale (ALSFRS), and survival. RESULTS: Patients treated with topiramate showed a faster decrease in arm strength (33.3%) during 12 months (0.0997 vs 0.0748 unit decline/month, p = 0.012). Topiramate did not significantly alter the decline in FVC and ALSFRS or affect survival. Topiramate was associated with an increased frequency of anorexia, depression, diarrhea, ecchymosis, nausea, kidney calculus, paresthesia, taste perversion, thinking abnormalities, weight loss, and abnormal blood clotting (pulmonary embolism and deep venous thrombosis). CONCLUSIONS: At the dose studied, topiramate did not have a beneficial effect for patients with ALS. High-dose topiramate treatment was associated with a faster rate of decline in muscle strength as measured by MVIC and with an increased risk for several adverse events in patients with ALS. Given the lack of efficacy and large number of adverse effects, further studies of topiramate at a dose of 800 mg or maximum tolerated dose up to 800 mg/day are not warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.61.4.456

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 203

Metadata

Authors
Cudkowicz, M. E., Shefner, J. M., Schoenfeld, D. A., Brown Jr., R. H., Johnson, H., Qureshi, M., Jacobs, M., Rothstein, J. D., Appel, S. H., Pascuzzi, R. M., Heiman-Patterson, T. D., Donofrio, P. D., David, W. S., Russell, J. A., Tandan, R., Pioro, E. P., Felice, K. J., Rosenfeld, J., Mandler, R. N., Sachs, G. M., Bradley, W. G., Raynor, E. M., Baquis, G. D., Belsh, J. M., Novella, S., Goldstein, J., & Hulihan, J.
Venue
Neurology
Published
2003-08-26
Volume
61
Issue
4
Pages
456-464
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2064471644
Cited by
203
References
3
FWCI
10.77
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.1212/wnl.61.4.456
The paper
Cudkowicz, M. E., Shefner, J. M., Schoenfeld, D. A., Brown Jr., R. H., Johnson, H., Qureshi, M., Jacobs, M., Rothstein, J. D., Appel, S. H., Pascuzzi, R. M., Heiman-Patterson, T. D., Donofrio, P. D., David, W. S., Russell, J. A., Tandan, R., Pioro, E. P., Felice, K. J., Rosenfeld, J., Mandler, R. N., . . . Hulihan, J. (2003). A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. https://doi.org/10.1212/wnl.61.4.456

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.